Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A pegylated form of Mechano Growth Factor, a splice variant of IGF-1 produced in response to mechanical stress on muscle tissue. The PEG (polyethylene glycol) modification extends the half-life from minutes to hours. Studied for muscle repair, hypertrophy, and recovery from injury. One of the 12 peptides removed from Category 2 in April 2026.
A synthetic 15-amino acid peptide derived from a protective protein found in human gastric juice. One of the most widely researched peptides for tissue repair and recovery.
MGF is produced when muscle tissue is damaged or mechanically loaded. It activates satellite cells (muscle stem cells) and promotes their proliferation and differentiation into new muscle fibers. The PEG modification prevents rapid degradation, allowing sustained signaling. Works through the IGF-1 receptor but with distinct downstream effects from systemic IGF-1.
BPC-157 promotes angiogenesis (new blood vessel formation), upregulates growth factor expression, and modulates nitric oxide synthesis. It appears to accelerate healing of tendons, ligaments, muscles, and the GI tract through multiple pathways including the FAK-paxillin pathway.
- Muscle repair and recovery
- Hypertrophy support
- Injury rehabilitation
- Age-related muscle loss (sarcopenia)
- Athletic recovery protocols
- Tendon and ligament repair
- Gut healing and GI protection
- Muscle injury recovery
- Joint health
- Post-surgical recovery
- Injection site pain and swelling
- Hypoglycemia risk
- Potential for uncontrolled cell proliferation
- Limited human safety data
- Banned by WADA in competitive sports
- Limited human clinical trial data
- Most research is animal-based
- Potential interactions with blood pressure medications
- Injection site reactions
- Long-term safety profile unknown
Removed from Category 2 on April 22, 2026. Scheduled for PCAC Group 2 review (by February 2027). Not FDA-approved for any indication. Previously restricted under Category 2 since September 2023.
PCAC: 2027-02-01
On April 15, 2026, the FDA announced BPC-157 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. It is now scheduled for formal PCAC (Pharmacy Compounding Advisory Committee) review on July 23, 2026, to determine whether it should be added to the 503A bulk drug substances list. Removal from Category 2 does not authorize compounding — pharmacies should exercise caution until PCAC issues its recommendation. Previously reclassified to Category 1 in February 2026, a step that is now superseded by this more formal process.
PCAC: July 23, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.